论文部分内容阅读
AIM:To prospectively determine the safety and tolerability of oral L-selenomethionine(SLM)with concurrent chemoradiation(CCRT)for StageⅢnon-small cell lung cancer(NSCLC)and estimate if the incidence and/or severity of adverse events could be reduced by it